University of California, Los Angeles (UCLA), Health Sciences

ACTG Announces Launch of Novel Clinical Trial Testing Multiple Therapeutics to Treat COVID-19

Study Design includes Phase 2 and Phase 3 Elements to Rapidly Identify and Evaluate Potential Treatments for non-Hospitalized Adults with COVID-19

Newswise — Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the world’s largest and longest established HIV research network, today announced the initiation of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which will be conducted by the ACTG. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple promising investigational agents for treating early COVID-19 in a single trial. There is currently no approved vaccine or therapeutic to prevent or treat COVID-19. For information about enrolling in the trial, please click here

ACTIV-2 will evaluate the safety and efficacy of investigational agents to treat adults who have COVID-19 illness but do not require hospitalization. The study will also enable researchers to assess the correlation between changes in viral shedding and clinical outcomes, leading to a better understanding of whether effective medications can reduce or halt the transmission of SARS-CoV-2 (the virus that causes COVID-19) to others. ACTIV-2 is a randomized, blinded, controlled adaptive platform that allows promising investigational agents to be added and removed over the course of the study, in order to efficiently test a variety of new agents against placebo within the same trial infrastructure. 

“Early treatment of COVID-19 will be vital to help us prevent advanced illness, hospitalization, and transmission of SARS-CoV-2,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles. “ACTIV-2 is designed to help us rapidly identify treatments that have the potential to radically alter the current pandemic landscape. Individuals who have recently been diagnosed with COVID-19 and are not hospitalized have the opportunity to make a huge contribution by participating in this study.” 

ACTIV-2 has been launched at 25 U.S.-based ACTG sites and will expand to include approximately 100 total sites (ACTG and non-ACTG), in both the United States and around the world. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), which also funds the ACTG. ACTIV-2 is part of NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership program to create a coordinated research strategy that prioritizes and speeds development of the most promising treatments and vaccines. It is also receiving support from Operation Warp Speed, the U.S. government’s multi-agency effort to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. 

In phase 2 of ACTIV-2, investigational agents will be studied to determine their safety, antiviral activity, and ability to reduce the duration of COVID-19 symptoms over 28 days. These agents will be selected based on the presence of in vitro data demonstrating activity against SARS-CoV-2 and phase 1 pharmacokinetics and safety data. In phase 2, 110 participants will receive the investigational agent and be compared to 110 participants randomized to receive placebo. If an agent demonstrates positive results and meets study-defined criteria for further evaluation, it will advance from phase 2 to phase 3. The phase 3 studies will evaluate the ability of each investigational agent to prevent hospitalization and death in non-hospitalized adults with COVID-19; 1,000 participants will receive the investigational agent (inclusive of the 110 participants from phase 2) and be compared to 1,000 participants randomized to placebo. 

To qualify for the study, participants must have tested positive for SARS-CoV-2 infection in the outpatient setting within seven days and started experiencing symptoms within 10 days of enrolling into the study. At least half of participants will have factors that put them at “high risk” of progressing to severe COVID-19, including being age 55 or older and having one of the following conditions: chronic lung, kidney, or liver disease; obesity; hypertension; cardiovascular disease; diabetes; or moderate to severe asthma. The ACTG is committed to enrolling individuals most impacted by COVID-19 and will work closely with community partners to make participation in the trial available to those who are often underrepresented in clinical research. 

The trial is being led by protocol chair Davey Smith, M.D., University of California, San Diego, along with Kara W. Chew M.D., M.S., University of California, Los Angeles (UCLA), David Alain Wohl, M.D., University of North Carolina (UNC), and Eric S. Daar, M.D., UCLA. It is supported by ACTG Chair Judith Currier, M.D., M.Sc., UCLA and ACTG Co-Chair Joseph J. Eron, M.D., UNC. 

“We have learned a lot about COVID-19 in the past few months – while people may start off with just a few minor symptoms, they can rapidly become very ill, and this is true of both young and older people,” said Dr. Smith. “We desperately need a treatment that can prevent people from progressing to advance disease and requiring hospitalization. We are hopeful that ACTIV-2 will identify some of those treatments, which we believe will have a profound impact on the health of people who acquire COVID-19.”

The first investigational agent to be evaluated by ACTIV-2 is LY3819253, an experimental monoclonal antibody treatment made by Lilly Research Laboratories in partnership with AbCellera Biologics. AbCellera and the Vaccine Research Center at NIAID identified the antibody from a blood sample of one of the first people in the United States to recover from COVID-19.

For more information about ACTIV-2, please visit the study website or www.actgnetwork.org.

 

About the AIDS Clinical Trials Group (ACTG)

Founded in 1987, the AIDS Clinical Trials Group (ACTG) was the world’s first HIV research network. The ACTG conducts groundbreaking studies to improve the treatment of HIV and its complications, reduce new infections and HIV-related illness, and advance new approaches to prevent, treat, and ultimately cure HIV in adults and children. ACTG investigators and research units in 12 countries serve as major resources for HIV/AIDS research, treatment, care, and training/education in their communities. ACTG studies have helped establish current paradigms for managing HIV disease, and have informed HIV treatment guidelines, resulting in dramatic decreases in HIV-related mortality worldwide.




Filters close

Showing results

110 of 3385
Released: 24-Sep-2020 11:15 AM EDT
Preparing for asthma attacks during a pandemic
University of Texas Health Science Center at Houston

Cooler weather, pumpkins, and falling leaves – all things that kick off the most wonderful time of year, the holiday season. But for asthma sufferers, this could mean trouble because experts see an increase in asthma attacks toward the end of September.

Newswise: Double-lung transplant for COVID-19 patient performed by team of UTHealth physicians
Released: 24-Sep-2020 11:10 AM EDT
Double-lung transplant for COVID-19 patient performed by team of UTHealth physicians
University of Texas Health Science Center at Houston

Just 12 hours after undergoing a double-lung transplant, 70-year-old Francisco Medellin was sitting up in a chair pushing bike pedals – a seemingly simple act that was the culmination of hard work by a dedicated multidisciplinary team from McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth).

Released: 24-Sep-2020 10:45 AM EDT
Uncovering a ‘suPAR’ culprit behind kidney injury in COVID-19
Michigan Medicine - University of Michigan

A new observational study finds patients in the hospital for COVID-19 have high levels of soluble urokinase receptor (suPAR), an immune-derived pathogenic protein that is strongly predictive of kidney injury.

Released: 24-Sep-2020 10:35 AM EDT
Climate pledges 'like tackling COVID-19 without social distancing'
University of Exeter

Current global pledges to tackle climate change are the equivalent of declaring a pandemic without a plan for social distancing, researchers say.

Released: 24-Sep-2020 10:10 AM EDT
Rebound or Permanent Slump? Possible Impacts of US COVID-19 Fiscal Policies
University of Virginia Darden School of Business

Fiscal policy is a powerful tool to combat economic downturns, but the results depend on decreasing inequality, an imperative to the efficacy of fiscal multipliers. As COVID-19 cases rise, new research offers insights into which fiscal policies may bolster the economy — and the other options, which may have long-term ramifications.

access_time Embargo lifts in 2 days
Embargo will expire: 24-Sep-2020 2:00 PM EDT Released to reporters: 24-Sep-2020 9:25 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 24-Sep-2020 2:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 24-Sep-2020 5:05 AM EDT
Many Americans continue to maintain unhealthy lifestyle habits during COVID-19; overeating, alcohol drinking and marijuana use increase while exercise declines, reports USC Center for the Digital Future
USC Annenberg School for Communication and Journalism

After more than six months of living in a pandemic, large percentages of Americans continue to indulge in unhealthy lifestyle habits, including overeating and increased use of alcohol and marijuana — all while many are exercising less, according to a study of the cultural impact of COVID-19 conducted by the USC Center for the Digital Future (CDF).

Newswise: Houston Methodist COVID-19 study shows rapid spread and potential for mutant viruses
Released: 23-Sep-2020 4:55 PM EDT
Houston Methodist COVID-19 study shows rapid spread and potential for mutant viruses
Houston Methodist

Molecular analysis of COVID-19’s powerful second wave in Houston shows a mutated virus strain linked to higher transmission and infection rates than the coronavirus strains that caused Houston’s first wave. Gene sequencing results from 5,085 COVID-positive patients tested at Houston Methodist since early March show a virus capable of adapting, surviving and thriving – making it more important than ever for physician scientists to understand its evolution as they work to discover effective vaccines and therapies.

Newswise: Likely molecular mechanisms of SARS-CoV-2 pathogenesis are revealed by network biology
Released: 23-Sep-2020 4:00 PM EDT
Likely molecular mechanisms of SARS-CoV-2 pathogenesis are revealed by network biology
University of Alabama at Birmingham

Researchers combined a lung-epithelial cell host interactome with a SARS-CoV-2 interactome. Network biology analysis of this human/SARS-CoV-2 interactome revealed potential molecular mechanisms of pathogenesis for SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

Newswise: Statins Reduce COVID-19 Severity, Likely by Removing Cholesterol That Virus Uses to Infect
Released: 23-Sep-2020 3:45 PM EDT
Statins Reduce COVID-19 Severity, Likely by Removing Cholesterol That Virus Uses to Infect
University of California San Diego Health

Analyzing anonymized patient medical records, UC San Diego researchers discovered that cholesterol-lowering statins reduced risk of severe COVID-19 infection, while lab experiments uncovered a cellular mechanism that helps explain why.


Showing results

110 of 3385

close
2.84809